SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. - Wikidata - awgldk - TriplyDB

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q33589653

about

Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes.Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.Randomized controlled trials: a solid platform for observational research.Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?

P2860

Q47102317-DE551CFF-B727-495A-AE10-C14736CBC92D Q47245549-CB26C487-9BD1-4F6A-A110-74AA8DFAF358 Q53786641-5B97BFCC-12F7-485D-BEE6-E2F1D6F30A3C Q57484162-4DF46729-A621-4981-88D0-26DB676C7139

P2860

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q33589653

description

2017 nî lūn-bûn

@nan

2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

SERAPHIN haemodynamic substudy ...... lmonary arterial hypertension.

@ast

SERAPHIN haemodynamic substudy ...... lmonary arterial hypertension.

@en

SERAPHIN haemodynamic substudy ...... lmonary arterial hypertension.

@nl

type

label

SERAPHIN haemodynamic substudy ...... lmonary arterial hypertension.

@ast

SERAPHIN haemodynamic substudy ...... lmonary arterial hypertension.

@en

SERAPHIN haemodynamic substudy ...... lmonary arterial hypertension.

@nl

prefLabel

SERAPHIN haemodynamic substudy ...... lmonary arterial hypertension.

@ast

SERAPHIN haemodynamic substudy ...... lmonary arterial hypertension.

@en

SERAPHIN haemodynamic substudy ...... lmonary arterial hypertension.

@nl

P1433

Q33589653-A30B600D-5B92-42BD-92A9-B8AA00CBE678

P1476

Q33589653-39AFC1EC-4881-404A-B90E-EEB7A0C84D97

P2093

Q33589653-29A3A69B-FB26-4BD6-AACF-80F7FC12A584

Q33589653-2A55583F-F91C-49A4-AD5C-2BC91AEE7E0A

Q33589653-2E02AD3C-3F34-4548-9641-FBA1E8DCFB0C

Q33589653-322F1851-04AD-49E7-AFE6-35EB3EF6EF75

Q33589653-46B544F8-796F-443E-8063-9EBC7E7D6BAB

Q33589653-657BA5A3-A4D1-40C1-8F37-6950E8534D91

Q33589653-768B2AE1-0F1F-4790-B8EE-7C95B3376C3D

Q33589653-A5626F09-1636-4D25-AE11-E95DAAB6CA00

Q33589653-C4494CD9-C433-491E-A137-4B45F0BA50A2

Q33589653-E0FDB033-982C-4078-9AFF-73A1BCB161F8

P2860

Q33589653-00B63641-D3A7-4EFF-B7AF-549C78D1B459

Q33589653-0F73E751-B153-457A-81FA-3E36A727D42C

Q33589653-272364F6-BC86-4C42-8983-1F6E640B40FF

Q33589653-2920B544-2FFE-46CE-A671-0199A26D3251

Q33589653-2C11F282-EF7C-4AB2-AD0A-5CC733E67CE4

Q33589653-35E2EDEB-6295-447A-A820-919F30A1FBC6

Q33589653-4E484AD2-94FF-4B34-84C2-FBC9336ADAC7

Q33589653-6A1AA6C5-79A3-4EA5-90C8-828B1390D1B2

Q33589653-825796C4-EF0D-44AA-A73D-E49772E9392A

Q33589653-82BB7F06-0D1A-4A47-9ECF-292A56815924

P304

Q33589653-AA41DDBC-54CC-463E-825F-D1984FEA8B19

P31

Q33589653-2C777AB2-BD10-46DA-B6F6-8828F762166C

P356

Q33589653-60A0723F-E723-4098-AAA7-D2B2E9D34502

P433

Q33589653-9A2361E9-1D37-49B0-8259-5C855A48FF5F

P478

Q33589653-C33D262A-7E66-4814-A6E1-54A934F2483B

P50

Q33589653-0BEB11A1-01F5-44DD-8E5E-FE0C7B99528E

Q33589653-0C7BC3CD-9E39-42F6-927E-740C46B8CB6C

Q33589653-10C2C097-41AC-4162-84AF-5EC0C37C8894

Q33589653-317663B9-D46A-404D-90E3-3AA7402F22F0

Q33589653-AB06ECA9-D2DD-496A-B9D7-4BCF57C58024

P577

Q33589653-C819827A-62D2-4AA9-BE83-636D4C2EEC96

P698

Q33589653-921A2990-A3CA-499C-B6D8-3FE3EB96FAEA

P921

Q33589653-19C93467-5DD2-42BF-8C82-7FCE41EC6145

Q33589653-CD3D802A-8DBB-4AEF-927D-717BDFA0838F

P932

Q33589653-7E930002-9ACE-4F81-B0D2-DD287E0CB2C0

P356

P1433

European Heart Journal

P1476

SERAPHIN haemodynamic substudy ...... ulmonary arterial hypertension

@en

P2093

B K S Sastry

http://www.w3.org/2001/XMLSchema#string

Franck-Olivier Le Brun

http://www.w3.org/2001/XMLSchema#string

Gérald Simonneau

http://www.w3.org/2001/XMLSchema#string

Lewis J Rubin

http://www.w3.org/2001/XMLSchema#string

Loïc Perchenet

http://www.w3.org/2001/XMLSchema#string

Marion Delcroix

http://www.w3.org/2001/XMLSchema#string

Nazzareno Galiè

http://www.w3.org/2001/XMLSchema#string

Richard N Channick

http://www.w3.org/2001/XMLSchema#string

Sanjay Mehta

http://www.w3.org/2001/XMLSchema#string

Tomás Pulido

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment goals of pulmonary hypertension

Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension.

Survival in pulmonary hypertension in Spain: insights from the Spanish registry.

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):

The right ventricle in pulmonary hypertension.

Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease.

P304

1147-1155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHX025

http://www.w3.org/2001/XMLSchema#string

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

Ardeschir Ghofrani

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28329315

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension

P932

5400052

http://www.w3.org/2001/XMLSchema#string